Evidence map›Paper›PMID 42614716›Full record

ArticleMolecular and clinical oncology2026

AXL is associated with STAT3 activation in breast cancer.

Guoan Zhang, Xiaobai Sun, Junping Zhang, Zhaozhen Zhang, Xinlin Luan, Fengyuan Yu, Zhenjie Guan, Changming Guo, Yangyang Hu, Mengfei Zhao and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Guoan ZhangSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Xiaobai SunDepartment of Medical Technology, Jinan Vocational College of Nursing, Jinan, Shandong 250102, P.R. China.
Junping ZhangDepartment of Pathology, Liangshan People's Hospital, Jining, Shandong 272600, P.R. China.
Zhaozhen ZhangSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Xinlin LuanSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Fengyuan YuSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Zhenjie GuanSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Changming GuoSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Yangyang HuSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Mengfei ZhaoSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Jiarong ESchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Yingxin XiongSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Junze LiuSchool of Forensic Medicine, Jining Medical University, Jining, Shandong 272067, P.R. China.
Yuqing HuSchool of Mental Health (Research Institute of Mental Health), Jining Medical University, Jining, Shandong 272067, P.R. China.
Xinyu MaSchool of Mental Health (Research Institute of Mental Health), Jining Medical University, Jining, Shandong 272067, P.R. China.
Ruiyao YangSchool of Mental Health (Research Institute of Mental Health), Jining Medical University, Jining, Shandong 272067, P.R. China.
Jianli LiuDepartment of Pathology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, P.R. China.
Hongli ZhaoDepartment of Gastroenterology, Digestive Diseases Hospital of Shandong First Medical University, Jining, Shandong 272067, P.R. China.
Qingwei GuoDepartment of Hematology and Oncology, and Department of Child Health, Jinan Children's Hospital, Jinan, Shandong 250022, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) represents one of the most frequently occurring malignancies and a primary cause of cancer-associated mortality among women globally. AXL, a receptor tyrosine kinase of the TAM family, and signal transducer and activator of transcription 3 (STAT3) are both aberrantly activated in BC and contribute to tumor progression. The present study aimed to investigate the functional association between AXL and STAT3 activation in BC. It was found that the overexpression of AXL in MCF7 and 293T cells enhanced STAT3 phosphorylation and transcriptional activity, whereas AXL knockdown using short hairpin RNA or pharmacological inhibition with R428 suppressed STAT3 activation. AXL overexpression also enhanced the secretion of IL-6, a major upstream activator of STAT3. Bioinformatics analysis of clinical BC datasets (GSE102484, GSE9893 and The Cancer Proteome Atlas) validated a positive correlation between AXL expression and STAT3 signaling activation. Collectively, these findings demonstrate that AXL is associated with STAT3 activation in BC, providing insight into the molecular pathways driving BC progression and uncovering candidate therapeutic targets.

Indexed as

AXLbreast cancersignal transducer and activator of transcription 3

Identifiers

PMID42614716
PMCPMC13483259

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.